



INVESTOR PRESENTATION

Q1 AND Q2 2011  FY 12

This presentation contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of SomnoMed's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the Company's results to differ materially from those expressed or implied by such forward-looking statements include but are not limited to, development and commercialisation of the Company's product portfolio; development or acquisition of additional products; and other risks and uncertainties. SomnoMed undertakes no duty to update any of these forward-looking statements to confirm them to actual.

Topics



FINANCIAL HIGHLIGHTS
1st Half FY 2012 vs. FY 2011



OVERVIEW
by Region




OUTLOOK
Q3 & Q4

Key points 1st Half FY 11/12

- Estimated sleep apnea therapy global market growth ~ 12-15% p.a. unchanged
- SomnoMed performance trending in line with guidance FY 11/12
- U.S. Medicare reimbursement for the entire product platform SomnoDent
- Opening of new SomnoMed subsidiaries in Germany and France
- Acquisition of oral appliance distribution partner in Holland
- Continued investment in growth, innovation & operational excellence


Financial Highlights

1st Half FY 2012 vs 1st Half FY 2011





SomnoDent unit sales

CAGR UNITS 62% TO DECEMBER 2011




UNIT CONTRIBUTION PER REGION TO DECEMBER 2011



SomnoMed Progress

Half Year to December



Financial Performance

FINANCIAL SUMMARY (\$000'S)	11/12 1st H	10/11 1st H	09/10 1st H	08/09 1st H	07/08 1st H	06/07 1st H
Units	14,443	11,450	9,140	5,475	2,916	1,870
Revenue	6,846	5,975	4,989	3,180	1,497	1,104
Gross Margin <i>Gross Margin%</i>	4,515 66.0%	3,825 64.0%	2,847 57.1%	1,655 52.0%	728 48.6%	486 44.0%
Operating profit before corporate, research and business development expenses, non cash items and income tax	1,506	1,495	1,098	(140)	(490)	(991)
Corporate, research and business development expenses	(1,260)	(1,101)	(832)	(931)	(788)	(540)
Depreciation amortization non cash items	(258)	(133)	(126)	(311)	(308)	(227)
Interest received and other cash items	71	50	46	155	88	33
Net profit / (loss) before tax	59	311	186	(1,227)	(1,498)	(1,725)

Investment in Growth, Innovation & Operational Excellence

- Growth ~ \$750k:
 - U.S. Sales and Marketing
 - Acquisition and opening new subsidiaries in EU
 - Global MATRx Marketing pre-FDA clearance
- Innovation & Operational Excellence ~ \$400k:
 - G2 design and FDA registration
 - ISO 13485 certification of production facility
 - Global Regulatory Affairs/Quality Assurance


Highlights by Region



Highlights by Region



Highlights by Region



Outlook 2nd Half FY 11/12

BUSINESS PERFORMANCE ON TRACK WITH GUIDANCE FY 11/12

- Expected market launch in Q4* of SomnoDent G2 the next generation of the world's # 1 oral sleep apnea appliance. The SomnoDent G2 will again raise the standard in comfort, compliance and treatment for the patient and the doctor.
- Expected market launch in Q4* of SomnoMed MATRx a revolutionary breakthrough in the prediction of efficacy of an oral appliance in a full sleep study setting (PSG).

**Pending FDA clearance*

Thank you ...

for sharing our vision and
passion to grow SomnoMed
into a strong global company
with a bright future...



Contacts



Chairman

Dr Peter Neustadt

Chief Executive Officer

Mr Ralf Barschow

Address

Level 3,
20 Clarke Street
Crows Nest NSW 2065
Australia

Telephone

+61 (0)2 9467 0400

Website

www.somnomed.com.au